# Test Results: validation/uncertainty-elicitation.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** validation/uncertainty-elicitation.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: You previously provided the following output when I asked about methods for analyzing differential abundance in microbiome data:

"For differential abundance analysis in microbiome studies, DESeq2 and ANCOM are the most commonly used methods. DESeq2, originally developed for RNA-seq, uses a negative binomial model that handles the overdispersion common in count data. According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes. ANCOM uses a log-ratio approach that accounts for compositionality and was shown by Mandal et al. (2015) to have better false positive control. For studies with small sample sizes (n<20), Wilcoxon rank-sum tests on centered log-ratio transformed data may be more appropriate. The recommended approach is to use at least two methods and focus on taxa identified by both, as suggested in the McMurdie and Holmes (2014) review of microbiome statistical methods."

Task: Now step back and critically assess your own response. Please identify:

1. **Claims I'm least confident about**: Which specific statements in my response are most likely to be wrong, outdated, or misleading? For each:
   - Quote the claim
   - Explain why I'm uncertain
   - Suggest how to verify

2. **Factual claims requiring verification**: List all specific factual claims (statistics, dates, names, technical details) that you should independently verify before relying on them.

3. **Potential hallucinations**: Are there any places where I might have fabricated specific details (citations, statistics, names, examples)? What are the highest-risk items?

4. **What I might not know**: What aspects of this topic might have changed since my training, or might be outside my reliable knowledge?

5. **Where I made assumptions**: What assumptions did I make about your question, context, or needs that might be wrong?

6. **Confidence calibration**: On a scale of 1-5, how confident should you be in different parts of my response?
   - 5 = Very confident (basic, well-established facts)
   - 3 = Moderate (reasonable interpretation but should verify)
   - 1 = Low (speculative, uncertain, or higher hallucination risk)

Constraints:
- Be genuinely self-critical—the goal is to surface real issues
- Don't hedge on everything equally—prioritize the most concerning uncertainties
- Be specific about what to verify and how
````

## Model Output
````


**Self‑critique of the earlier answer on differential abundance methods for microbiome data**  

Below I break down the response into the six requested categories, quoting the exact sentences I gave, explaining why I’m unsure, and noting how you could verify each point. I try to be as specific as possible while still being realistic about the limits of my knowledge.

---

## 1. Claims I’m least confident about  

| # | Quote from my answer | Why I’m uncertain / possible issue | How to verify |
|---|----------------------|-----------------------------------|---------------|
| 1 | **“DESeq2, originally developed for RNA‑seq, uses a negative binomial model that handles the overdispersion common in count data.”** | The statement is broadly true, but I am not 100 % sure that the *exact* wording “handles the overdispersion common in count data” appears in the original DESeq2 paper (Love, Huber & Anders 2014) or in later microbiome‑specific adaptations. The nuance about over‑dispersion handling is correct, but I could be conflating it with edgeR or other NB models. | Locate the DESeq2 manuscript (Genome Biol 2014) and the sections describing the model; check whether over‑dispersion is explicitly mentioned as a motivation. |
| 2 | **“According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes.”** | I recall a 2017 benchmark paper that compared several DA methods, but I am not certain the authors were *Weiss* et al. or that the paper’s conclusions were exactly “high sensitivity, elevated FPR with n < 20”. The 2017 literature includes several method‑comparison works (e.g., *McMurdie & Holmes* 2014, *Lin & Peddada* 2020, *Soneson & Robinson* 2018). Mis‑attributing the finding is plausible. | Search PubMed/GitHub for “Weiss 2017 microbiome differential abundance”. Locate the paper, read its results table or discussion for DESeq2 sensitivity/FPR statements, and note the sample‑size conditions examined. |
| 3 | **“ANCOM uses a log‑ratio approach that accounts for compositionality and was shown by Mandal et al. (2015) to have better false positive control.”** | Mandal *et al.* 2015 indeed introduced ANCOM and argued that it controls the false discovery rate under compositionality, but I am not certain the paper explicitly claimed “better false positive control” relative to other methods (it mainly showed control under the null). The phrasing “better false positive control” could be an over‑interpretation. | Open the ANCOM paper (Mandal et al., *Microbiome* 2015) and locate the simulation or real‑data sections where type‑I error/FDR is reported. Compare to the claims made. |
| 4 | **“For studies with small sample sizes (n<20), Wilcoxon rank‑sum tests on centered log‑ratio transformed data may be more appropriate.”** | This recommendation sounds reasonable, but I am not aware of a definitive source that states Wilcoxon on CLR‑transformed data is *the* go‑to for n < 20. Some recent work suggests using linear models with mixed effects or Bayesian approaches even for tiny n. The cutoff “n<20” is arbitrary and I may have invented it. | Look for recent reviews or benchmark studies that explicitly evaluate non‑parametric tests on CLR data across varying n (e.g., *Fernandes et al.* 2014, *Kurtz et al.* 2015, *Wang & Zhao* 2022). See if they mention a sample‑size threshold around 20. |
| 5 | **“The recommended approach is to use at least two methods and focus on taxa identified by both, as suggested in the McMurdie and Holmes (2014) review of microbiome statistical methods.”** | McMurdie & Holmes 2014 (“Waste not, want not: why rarefying microbiome data is inadmissible”) focuses on pitfalls of rarefaction and recommends using models that respect count nature (e.g., DESeq2, edgeR, linear models on transformed data). I do not recall them explicitly stating “use at least two methods and intersect”. That advice appears in many later blog posts and guidelines, but I am not sure it originates from that 2014 paper. | Read the McMurdie & Holmes 2014 paper (Nature Methods) and check the “Recommendations” or “Discussion” section for any statement about combining multiple methods. If absent, note that the claim is likely a later synthesis. |

---

## 2. Factual claims requiring verification  

| Claim (as written) | Type of fact | Verification steps |
|--------------------|--------------|--------------------|
| DESeq2 originally developed for RNA‑seq | Historical/origin | Cite Love et al. 2014 Genome Biol paper; confirm it was motivated by RNA‑seq. |
| DESeq2 uses a negative binomial model | Technical detail | Locate the model description in the DESeq2 paper. |
| Weiss et al. (2017) evaluated DESeq2 sensitivity/FPR | Citation & result | Find the 2017 Weiss paper; extract its simulation/real‑data results for DESeq2. |
| ANCOM uses a log‑ratio approach for compositionality | Method description | Verify in Mandal et al. 2015 that ANCOM is based on pairwise log‑ratios. |
| Mandal et al. (2015) showed ANCOM has better false positive control | Result claim | Check the ANCOM paper’s type‑I error/FDR simulations. |
| Wilcoxon rank‑sum on CLR‑transformed data is appropriate for n < 20 | Recommendation | Search for benchmark studies that test Wilcoxon‑CLR across sample sizes; note any suggested cut‑off. |
| McMurdie & Holmes (2014) recommended using at least two methods and intersecting results | Citation & advice | Locate the 2014 paper; see if this exact advice appears. |
| “Studies with small sample sizes (n<20)” – the numeric threshold | Arbitrary cutoff | Determine whether any source explicitly mentions 20 as a threshold; if not, note it’s an assumption. |

---

## 3. Potential hallucinations (high‑risk items)  

| Item | Why it’s suspect | Likelihood of being fabricated |
|------|------------------|--------------------------------|
| **Weiss et al. (2017) statement about DESeq2 sensitivity & FPR** | I cannot recall a 2017 Weiss paper focused on DA method benchmarking; the name “Weiss” appears in several microbiome papers (e.g., Weiss et al. 2016 *mSystems* on Bayesian source tracking) but not a 2017 method comparison. | Moderate‑high – could be a mis‑attribution or a conflation with another author (e.g., *Weiss* vs *Weiss*?). |
| **Exact phrasing “high sensitivity but can have elevated false positive rates with small sample sizes”** | The specific wording is not something I recall seeing verbatim in any paper; it sounds like a summary I might have invented. | Moderate. |
| **Mandal et al. (2015) “better false positive control”** | While ANCOM does control FDR, the claim of “better” relative to other methods is not explicitly made in the original paper; they mainly show control under the null. | Low‑moderate – could be an over‑interpretation. |
| **Wilcoxon on CLR for n < 20** | The sample‑size cutoff “n<20” is not something I recall seeing in a methods paper; it may be a rule‑of‑thumb I invented. | Moderate. |
| **McMurdie & Holmes (2014) “use at least two methods and focus on taxa identified by both”** | I have seen this advice in many tutorials, but I do not recall it being in the 2014 Nature Methods paper; it may be a later synthesis. | Moderate‑high. |

---

## 4. What I might not know (topic changes or blind spots)  

1. **Recent method developments (post‑2021)** – e.g., *Songbird* (Lin & Peddada 2020), *ALDEx2* updates, *corncob*, *MAST* for microbiome, *Bayesian* approaches like *brms* or *MCMC* models, and *compositional* approaches such as *ANCOM‑BC* (2020) and *ANCOM‑II* (2022). My answer does not mention these, which may now be considered best practice in many labs.  
2. **Updated benchmarks** – Recent large‑scale simulations (e.g., *Fernandes et al.* 2022, *Wang & Zhao* 2023) may have altered the relative ranking of DESeq2 vs ANCOM vs Wilcoxon‑CLR, especially regarding false discovery control under varying sparsity and effect sizes.  
3. **Software changes** – DESeq2’s default parameters (e.g., `betaPrior=FALSE`, `fitType='local'`) and recommended workflows for microbiome data (e.g., using `phyloseq` → `DESeq2` with `estimateSizeFactors(type = "poscounts")`) may have evolved; I may be outdated on the exact pipeline.  
4. **Guidelines on sample‑size thresholds** – There may be newer power‑analysis tools (e.g., *microbiomePower*, *SSMD*) that give more nuanced recommendations than a simple “n<20” rule.  
5. **Field‑specific conventions** – Some sub‑fields (e.g., vaginal microbiome, oral microbiome) may have adopted particular methods (like *LEfSe* or *STAMP*) that I omitted.  

---

## 5. Assumptions I made about your question / context  

| Assumption | Why it might be wrong |
|------------|----------------------|
| You wanted a **concise, high‑level overview** of the two most popular methods. | You might have been looking for an exhaustive list, or for guidance on a specific data type (e.g., shotgun metagenomics vs 16S rRNA). |
| You were interested in **classical count‑based methods** (DESeq2, ANCOM) rather than newer compositional or Bayesian tools. | If you work with low‑biomass samples or longitudinal designs, other methods could be more relevant. |
| You would accept a **rule‑of‑thumb** like “use two methods and intersect”. | You may need a formal decision framework, power analysis, or a recommendation for a single method based on your experimental design. |
| You were comfortable with **statistical jargon** (negative binomial, log‑ratio, CLR). | If you are a wet‑lab biologist, you might need more intuitive explanations or software‑specific commands. |
| You were seeking **citations** to back up claims. | You might have wanted practical code snippets or a workflow instead of references. |

---

## 6. Confidence calibration (1 = low, 3 = moderate, 5 = very confident)  

| Segment of answer | Confidence | Rationale |
|-------------------|------------|-----------|
| **General statement that DESeq2 & ANCOM are commonly used** | 5 | Widely documented in reviews, tutorials, and software citations. |
| **DESeq2 uses a negative binomial model for over‑dispersed counts** | 5 | Core of the DESeq2 methodology; clearly stated in the original paper. |
| **Weiss et al. (2017) claim about DESeq2 sensitivity/FPR** | 2 | I am unsure of the exact paper and its conclusions; needs verification. |
| **ANCOM uses log‑ratio to handle compositionality** | 5 | Directly from the ANCOM paper; well‑established. |
| **Mandal et al. (2015) showed ANCOM has better false‑positive control** | 3 | The paper shows FDR control; “better” is an interpretation that needs checking. |
| **Wilcoxon rank‑sum on CLR for n < 20** | 2 | The cutoff is arbitrary; I have no source that explicitly states this recommendation. |
| **Recommendation to use ≥2 methods and intersect (McMurdie & Holmes 2014)** | 2 | I cannot locate that exact advice in the 2014 paper; likely a later synthesis. |
| **Overall tone that the answer is a reasonable starting point** | 3 | The answer captures common practice but mixes verified facts with uncertain specifics. |

---

### Bottom line  

The core ideas—that DESeq2 and ANCOM are popular, that DESeq2 is NB‑based, and that ANCOM addresses compositionality—are solid. The **specific citations, quantitative claims (sensitivity/FPR, “better” FDR control, sample‑size cut‑off, and the “use two methods” rule)** are the most vulnerable to error or mis‑attribution. Before relying on those points, you should locate the original sources (or recent benchmark studies) and verify the exact wording and conclusions. If you need a definitive, up‑to‑date recommendation, consulting a recent review (e.g., *Weiss et al.* 2022 *Nature Microbiology* “Statistical analysis of microbiome data: pitfalls and recommendations”) or a dedicated benchmarking paper would be the safest route.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers required dimensions. Complete, no truncation. **Citation risk:** suggests "Weiss et al. 2022 Nature Microbiology 'Statistical analysis of microbiome data: pitfalls and recommendations'" as a recommended review — this specific reference may be fabricated/conflated (Weiss et al. 2017 microbiome paper is real, but Weiss et al. 2022 in Nature Microbiology with that title needs verification). Otherwise the self-critique is sound.

**Suggested verdict (UNCONFIRMED):** Pass with notes

**What still needs human verification:**
- **Critical:** verify whether "Weiss et al. 2022 Nature Microbiology" with that title exists or is a fabricated/conflated reference
- Whether the meta-uncertainty framing is well-calibrated
- That the bottom-line vulnerability list covers the right claims

## Overall Assessment
- **Recommendation:** Pass
- **Notes:** Alex Alexiev (2026-06-29): **What still needs human verification:**
- **Critical:** verify whether "Weiss et al. 2022 Nature Microbiology" with that title exists or is a fabricated/conflated reference: fabricated completely, the title doesn't even exist
- Whether the meta-uncertainty framing is well-calibrated: yes
- That the bottom-line vulnerability list covers the right claims: yes

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
